Kinnate Biopharma Inc.
Kinnate Biopharma Inc. (KNTE) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
knte · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Kinnate Biopharma Inc. (KNTE) measures how much investors pay for each dollar of the company's trailing earnings. KNTE's current PE ratio of N/A is calculated by dividing its stock price of $2.65 by its TTM earnings per share of -$2.42.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2018 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Kinnate Biopharma Inc.You KNTE | $125M | N/A | — | -$2.42 |
 Aadi Bioscience, Inc. AADI | $95M | N/A | — | -$0.03 |
 aTyr Pharma, Inc. ATYR | $46M | N/A | — | -$0.80 |
 Decibel Therapeutics, Inc. DBTX | $123M | N/A | — | -$2.52 |
 Graybug Vision, Inc. GRAY | $121M | N/A | — | -$0.00 |
 NGM Biopharmaceuticals, Inc. NGM | $129M | N/A | — | -$1.73 |
 Pardes Biosciences, Inc. PRDS | $135M | N/A | — | -$1.61 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-2.42 | — | |
2022-12-31 FY2022 | — | $-2.59 | — | |
2021-12-31 FY2021 | — | $-2.05 | — | |
2020-12-31 FY2020 | — | $-0.81 | — | |
2019-12-31 FY2019 | — | $-0.28 | — | |
2018-12-31 FY2018 | — | $-0.18 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Kinnate Biopharma Inc. (KNTE) measures how much investors pay for each dollar of the company's trailing earnings. KNTE's current PE ratio of N/A is calculated by dividing its stock price of $2.65 by its TTM earnings per share of -$2.42.
Frequently asked questions
KNTE pe ratio · 6 questionsKNTE's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.65 and TTM EPS of -$2.42. Data sourced from Financial Modeling Prep via KNTE's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Kinnate Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09